Dr. Swagat Tripathy

Qualification             : Ph.D., M. Pharm (Pharmaceutics), PGDBM, PRINCE2^®

Specialization            : Pharmaceutical Strategy, Product Lifecycle Management, Regulatory Affairs, Project & Portfolio Management, Business Transformation

E mail                         : swagat.tripathy@nmims.edu

Phone                         : 022-42332000 (Extn- 2036)

Experience                 : 18 years (Industry – 17 years, Academics – 1 years+)

Profile

Dr. Swagat Tripathy has 18 years of experience across the pharmaceutical industry and academia.

In his industry career, he has worked with pharmaceutical organisations including Biocon, Dr. Reddy’s Laboratories, Aurobindo, Cipla, Apotex, Ipca and Bliss GVS, with experience spanning pharmaceutical strategy, product lifecycle management, regulatory strategy, project and portfolio management, strategic alliances and business transformation across global markets.

In his academic career, Dr. Tripathy brings an industry perspective to pharmaceutical education, with interests in pharmaceutical innovation, regulatory intelligence, AI-enabled transformation, digital therapeutics and industry–academia collaboration.

Interest areas:  

• Pharmaceutical Strategy & Product Lifecycle Management
• Regulatory Strategy & Regulatory Intelligence
• Enterprise PMO, Project & Portfolio Management
• New Product Development & Commercialization
• Pharmaceutical Innovation & Business Transformation
• AI, Digital Transformation & Digital Therapeutics
• Industry-Academia Collaboration
• Executive Education & Applied Learning

Research

• Publications – 23 (International- 21, National- 2)
• Book Chapters- 5
• Presentations- 24 as resource-speaker and presenter

Academic activities

He has guided 30 no. of M.Pharm. students for their research projects. 

Awards

• Most Resilience PM Award – Dr. Reddy’s Laboratories, for contribution to critical deliverables during the COVID period.
• All-rounder Project Manager – Biocon.
• Performance-based Manager Excellence Award and Best Service Award – Apotex.

Recent Publications

1. V Prajapati, S Tripathy, H Dureja (2013), Product lifecycle management through patents and regulatory strategies, Journal of Medical Marketing 13 (3), 171-180
2. S Tripathy, V Prajapati (2014), Mergers and acquisitions: Trends in Indian pharmaceutical industry, Journal of Medical Marketing 14 (4), 182-190
3. M Saini, S Tripathy, H Dureja (2014), USA FDA’s implementation of QbD and GDUFA: A wakeup call for other regulatory agencies across the globe, Journal of Medical Marketing 14 (2-3), 108-114
4. Manisha, S. Tripathy, H Dureja (2014), Panoramic view on quality by design, Management 2 (2), 217-231
5. P Kaushik, S Tripathy, H Dureja (2014),Prospective of pricing in pharmaceutical environment,
   Applied Clinical Research, Clinical Trials and Regulatory Affairs 1 (3), 151-156.
6. S Tripathy, PN Murthy, BP Patra, H Dureja, JK Badjatya (2014), A pragmatic way to sustain in generic pharma environment: PLCM through regulatory strategies, International Journal of Drug Regulatory Affairs 2 (2), 31-48.
7. H Dureja, N Dalal, S Tripathy (2014), Big Pharma's Recent Challenges, Applied Clinical Research, Clinical Trials and Regulatory Affairs 1 (1), 28-36
8. K Dhull, S Tripathy, H Dureja (2015), Cosmetics: Regulatory scenario in USA, EU and India
   Journal of Pharmaceutical Technology, Research and Management 3 (2), 127-139
9. P Kumar, S Tripathy, H Dureja (2015), Pharma emerging market’s scaning by look and feel of its opportunities and challenges, Applied Clinical Research, Clinical Trials and Regulatory Affairs 2 (3), 115-122.
10. S Tripathy, V Prajapati, VK Sengodan Guruswamy (2015), Product Life Cycle Management for Pharmaceutical Innovation, Applied Clinical Research, Clinical Trials and Regulatory Affairs 2 (3), 145-152
11. P Kaushik, S Tripathy, R Sharma, H Dureja (2015), Anti-Monopoly and Competition Laws-Impact on the Indian Pharmaceutical Industry, Applied Clinical Research, Clinical Trials and Regulatory Affairs 2 (3), 153-157
12. D Chaudhary, S Tripathy, H Dureja (2015), Drug and Cosmetic Amendment Bill in India: A Promising Hope for Healthy Medical Device Regulatory Environment, Applied Clinical Research, Clinical Trials and Regulatory Affairs 2 (3), 133-136
13. J Yadav, S Tripathy, M Dahiya, H Dureja (2017), Emerging nutraceutical regulations in India, Applied Clinical Research, Clinical Trials and Regulatory Affairs 4 (2), 91-98
14. S Tripathy, P Pandey, S Mohanty, PN Murthy, V Sengodan Guruswamy (2017), Audit and Compliance-Bird's Eye on Current Indian Pharmaceutical Environment, Applied Clinical Research, Clinical Trials and Regulatory Affairs 4 (2), 114-119
15. M Saini, S Tripathy, PN Murthy, BP Partra, H Dureja, R Godhani (2017), ABC of Clinical Trials with the Mark of Safety, Efficacy and Transparency, Applied Clinical Research, Clinical Trials and Regulatory Affairs 4 (2), 120-127
16. S Tripathy, PN Murthy, BP Patra (2018), Integrating PLCM strategy in pharmaceutical emerging market, International Journal of Drug Regulatory Affairs, 21-32
17. D Purohit, M Saini, P Pandey, S Tripathy, H Dureja (2019), Implementation of Quality by Design: A Review
    Applied Clinical Research, Clinical Trials and Regulatory Affairs 6 (2), 99-111
18. S Sanduria, S Tripathy, PN Murthy, BP Patra, H Dureja (2020), Voicing regulatory perspectives of the combination products, Journal of Generic Medicines 16 (3), 101-111
19. P Rathee, S Tripathy, S Khatter, BP Patra, PN Murthy, H Dureja (2021),505 (b)(2)-A smart pathway to differentiate from competitive, low margin environment of generics
    Journal of Generic Medicines 17 (4), 183-194
20. S Tripathy, PN Murthy, BP Patra, P Mehra, H Dureja (2021), Challenges and prospects in Chinese pharmaceutical regulatory environment, Journal of Generic Medicines 17 (3), 106-114
21. Tripathy, S., Murthy, P. N., Patra, B. P., Sanduria, S., & Dureja, H. (2021). Endocrine Disruptors (EDs) Regulatory Waves: A Frictional Lens Perspective on Regulated and Emerging Markets. International Journal of Pharmaceutical Sciences and Drug Research, 13(2), 230–239. DOI: 10.25004/IJPSDR.2021.130218
22. S Tripathy, PN Murthy, BP Patra, S Sanduria, H Dureja (2022), Strategic archetype of herbal medicine product (HMP) in regulated and emerging market, Research Journal of Pharmacy and Technology 15 (5), 1973-1980.
23. T Hussian, S Tripathy, H Dureja (2025), Navigating the regulatory maze: a comparative analysis of digital therapeutics (DTx) regulations, Journal of Science and Technology Policy Management.